JP2024016209A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024016209A5 JP2024016209A5 JP2023191381A JP2023191381A JP2024016209A5 JP 2024016209 A5 JP2024016209 A5 JP 2024016209A5 JP 2023191381 A JP2023191381 A JP 2023191381A JP 2023191381 A JP2023191381 A JP 2023191381A JP 2024016209 A5 JP2024016209 A5 JP 2024016209A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- ctla
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023554P | 2020-05-12 | 2020-05-12 | |
| US63/023,554 | 2020-05-12 | ||
| PCT/EP2021/062695 WO2021228978A1 (en) | 2020-05-12 | 2021-05-12 | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies |
| JP2022554243A JP7387912B2 (ja) | 2020-05-12 | 2021-05-12 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554243A Division JP7387912B2 (ja) | 2020-05-12 | 2021-05-12 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024016209A JP2024016209A (ja) | 2024-02-06 |
| JP2024016209A5 true JP2024016209A5 (enExample) | 2024-05-08 |
Family
ID=75977756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554243A Active JP7387912B2 (ja) | 2020-05-12 | 2021-05-12 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
| JP2023191381A Pending JP2024016209A (ja) | 2020-05-12 | 2023-11-09 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554243A Active JP7387912B2 (ja) | 2020-05-12 | 2021-05-12 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210355224A1 (enExample) |
| EP (1) | EP4021940A1 (enExample) |
| JP (2) | JP7387912B2 (enExample) |
| KR (1) | KR20230009354A (enExample) |
| CN (1) | CN114729054A (enExample) |
| AU (3) | AU2021269832B2 (enExample) |
| BR (1) | BR112022021893A2 (enExample) |
| CA (1) | CA3158607A1 (enExample) |
| IL (2) | IL297640A (enExample) |
| MX (1) | MX2022006728A (enExample) |
| TW (2) | TW202535468A (enExample) |
| WO (1) | WO2021228978A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260077026A1 (en) * | 2022-09-07 | 2026-03-19 | The University Of Chicago | Methods for treating cancer with hyperactive adar enzymes |
| WO2025211692A1 (ko) * | 2024-04-02 | 2025-10-09 | (주)에트노바테라퓨틱스 | 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트 |
| WO2025256641A1 (zh) * | 2024-06-13 | 2025-12-18 | 江苏恒瑞医药股份有限公司 | 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| AU2003234090A1 (en) | 2002-04-11 | 2003-10-27 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for pulmonary administration |
| EP1494651A4 (en) | 2002-04-11 | 2010-10-13 | Medimmune Vaccines Inc | PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM |
| EP1572915A4 (en) | 2002-04-11 | 2011-01-05 | Medimmune Vaccines Inc | PRESERVATION OF BIOACTIVE MATERIALS BY SPRAY DRYING |
| AU2003230908A1 (en) | 2002-04-11 | 2003-10-27 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| AU2003297320B8 (en) | 2002-12-17 | 2008-02-21 | Medimmune, Llc | High pressure spray-dry of bioactive materials |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| UY36351A (es) * | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| HK1247578A1 (zh) * | 2015-04-01 | 2018-09-28 | Medimmune Limited | 用於治疗非小细胞肺癌的组合抗pd-l1和抗ctla4抗体 |
| EP3472207B1 (en) * | 2016-06-20 | 2021-01-20 | F-Star Delta Limited | Binding molecules binding pd-l1 and lag-3 |
| EP3519827A1 (en) * | 2016-09-27 | 2019-08-07 | Oncologie, Inc. | Methods for treating cancer with bavituximab based on levels of 2-glycoprotein 1, and assays therefor |
| JP2020515637A (ja) * | 2017-04-03 | 2020-05-28 | オンコロジー、インコーポレイテッド | 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法 |
| US11712418B2 (en) * | 2017-05-26 | 2023-08-01 | Bruin Biosciences, Inc. | Chemoembolization agents |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| US20210260051A1 (en) * | 2018-06-14 | 2021-08-26 | Board Of Regents, The University Of Texas System | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer |
| CN112543809A (zh) * | 2018-06-15 | 2021-03-23 | 米纳治疗有限公司 | 包含C/EBPα saRNA的组合疗法 |
-
2021
- 2021-05-12 US US17/318,017 patent/US20210355224A1/en active Pending
- 2021-05-12 AU AU2021269832A patent/AU2021269832B2/en active Active
- 2021-05-12 TW TW114101922A patent/TW202535468A/zh unknown
- 2021-05-12 JP JP2022554243A patent/JP7387912B2/ja active Active
- 2021-05-12 CN CN202180006543.2A patent/CN114729054A/zh active Pending
- 2021-05-12 MX MX2022006728A patent/MX2022006728A/es unknown
- 2021-05-12 IL IL297640A patent/IL297640A/en unknown
- 2021-05-12 EP EP21726376.3A patent/EP4021940A1/en active Pending
- 2021-05-12 BR BR112022021893A patent/BR112022021893A2/pt unknown
- 2021-05-12 KR KR1020227024530A patent/KR20230009354A/ko not_active Ceased
- 2021-05-12 WO PCT/EP2021/062695 patent/WO2021228978A1/en not_active Ceased
- 2021-05-12 CA CA3158607A patent/CA3158607A1/en active Pending
- 2021-05-12 US US17/765,585 patent/US20220363762A1/en active Pending
- 2021-05-12 IL IL311936A patent/IL311936A/en unknown
- 2021-05-12 TW TW110117153A patent/TWI870592B/zh active
-
2023
- 2023-11-09 JP JP2023191381A patent/JP2024016209A/ja active Pending
-
2024
- 2024-03-28 US US18/620,387 patent/US20240239893A1/en active Pending
- 2024-05-03 AU AU2024202963A patent/AU2024202963B2/en active Active
- 2024-11-28 AU AU2024266949A patent/AU2024266949A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016209A5 (enExample) | ||
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2007515469A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2024530310A (ja) | Ｔ細胞リンパ腫治療薬の調製におけるｅｚｈ２阻害剤の使用 | |
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2017031160A5 (enExample) | ||
| JP2009518441A5 (enExample) | ||
| RU2018146812A (ru) | Фармацевтические комбинации | |
| JP2021509395A5 (enExample) | ||
| JP2018522028A5 (enExample) | ||
| JPWO2019241442A5 (enExample) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2017537927A5 (enExample) | ||
| JPWO2022256500A5 (enExample) | ||
| JPWO2021123996A5 (enExample) | ||
| JPWO2021228978A5 (enExample) | ||
| WO2020233723A1 (zh) | 用于治疗头颈癌的喹啉衍生物 | |
| JPWO2021180821A5 (enExample) | ||
| JPWO2020159822A5 (enExample) | ||
| Kaul et al. | Review on pulse therapy: a novel approach in the treatment of pemphigus vulgaris | |
| JPWO2019144098A5 (enExample) | ||
| Bronson et al. | Το Market, Το Market-2012 | |
| JPWO2020061060A5 (enExample) | ||
| JP2020517648A5 (enExample) |